Teva Pharmaceutical Industries Ltd (NYSE:TEVA)’s share price was up 6.1% on Monday . The company traded as high as $7.44 and last traded at $7.44, approximately 18,343,414 shares traded hands during trading. An increase of 16% from the average daily volume of 15,806,336 shares. The stock had previously closed at $7.01.
A number of research firms recently issued reports on TEVA. Raymond James reduced their price objective on Teva Pharmaceutical Industries from $22.00 to $15.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. SunTrust Banks lowered their price objective on Teva Pharmaceutical Industries to $7.00 and set a “hold” rating for the company in a research note on Thursday, August 8th. Barclays began coverage on Teva Pharmaceutical Industries in a research report on Tuesday, June 11th. They issued an “underweight” rating and a $8.00 target price on the stock. Bank of America cut Teva Pharmaceutical Industries from a “buy” rating to an “underperform” rating and cut their target price for the company from $19.00 to $9.00 in a research note on Thursday, May 30th. Finally, Oppenheimer set a $12.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a report on Wednesday, June 12th. Six analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Hold” and an average target price of $12.80.
The firm has a market cap of $8.83 billion, a price-to-earnings ratio of 2.97, a P/E/G ratio of 0.78 and a beta of 1.68. The firm’s fifty day moving average is $7.21 and its two-hundred day moving average is $11.25. The company has a debt-to-equity ratio of 1.73, a current ratio of 0.96 and a quick ratio of 0.62.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, August 7th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.02. The firm had revenue of $4.34 billion during the quarter, compared to analyst estimates of $4.25 billion. Teva Pharmaceutical Industries had a negative net margin of 21.94% and a positive return on equity of 16.04%. Teva Pharmaceutical Industries’s revenue was down 7.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.78 EPS. On average, equities analysts forecast that Teva Pharmaceutical Industries Ltd will post 2.25 earnings per share for the current fiscal year.
Several large investors have recently modified their holdings of the company. First Interstate Bank acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at $28,000. Pacer Advisors Inc. acquired a new position in Teva Pharmaceutical Industries during the second quarter worth about $32,000. Kavar Capital Partners LLC acquired a new position in Teva Pharmaceutical Industries during the second quarter worth about $35,000. G&S Capital LLC grew its holdings in Teva Pharmaceutical Industries by 99.4% during the second quarter. G&S Capital LLC now owns 4,012 shares of the company’s stock worth $37,000 after acquiring an additional 2,000 shares during the period. Finally, NEXT Financial Group Inc raised its position in Teva Pharmaceutical Industries by 384.8% in the second quarter. NEXT Financial Group Inc now owns 4,276 shares of the company’s stock worth $39,000 after acquiring an additional 3,394 shares in the last quarter. 57.85% of the stock is owned by institutional investors.
Teva Pharmaceutical Industries Company Profile (NYSE:TEVA)
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Recommended Story: Understanding debt-to-equity ratio in fundamental analysis
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.